Hormonal
SGLT2 inhibitors (specifically empagliflozin) reduce cardiovascular mortality and heart failure hospitalization rates in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.
If you have Type 2 Diabetes and existing heart disease, empagliflozin (an SGLT2 inhibitor) significantly lowers your risk of dying from heart causes and being hospitalized for heart failure. This benefit happens regardless of how much your blood sugar drops, suggesting it protects the heart directly. While side effects like genital infections are possible, the life-saving benefits for high-risk patients are substantial. This drug class is also being studied for heart failure patients without diabetes.
The results of the recently published EMPA-REG OUTCOME trial... showed that the sodium–glucose co-transporter 2 (SGLT2) inhibitor empagliflozin was associated with a pronounced and precocious 38% reduction in cardiovascular mortality... These benefits were more related to a reduction in incident HF events rather than to ischaemic vascular endpoints.
Why this rating
Based on a large, randomized, controlled trial (EMPA-REG OUTCOME) with clear statistical significance, though the paper notes it was not designed specifically for HF patients.
Source
Moderated ePoster Session 2
Javed Butler et al. · European Journal of Heart Failure · 2014
DOI 10.1002/ejhf.933
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →